Morgan Stanley analyst Kristine Liwag maintains Howmet Aerospace (NYSE:HWM) with a Overweight and raises the price target from $45 to $47.
Chardan Capital Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $32
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $34 to $32.